Revance to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Revance Therapeutics (NASDAQ: RVNC) announced its participation in two upcoming investor conferences. CFO Tobin Schilke will present at the William Blair 44th Annual Growth Stock Conference on June 4, 2024, in Chicago. CEO Mark J. Foley will speak at the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami. Live audio webcasts will be accessible via Revance's Investor Relations webpage, with replays available for 90 days post-event.

Positive

• Revance’s participation in high-profile investor conferences signals strong investor engagement.
• Live webcasts and replays provide transparency and accessibility for investors.
• Presentations by senior leadership (CFO and CEO) may enhance investor confidence.

Negative

• No mention of new product releases or financial forecasts potentially leaves investors wanting more substantive updates.
• Participation in conferences alone may not significantly impact stock performance without accompanying positive news.

NASHVILLE, Tenn.--(BUSINESS WIRE)-- Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced that the company will be participating in the following investor conferences.

William Blair 44th Annual Growth Stock Conference
Chief Financial Officer Tobin Schilke is scheduled to present on Tuesday, June 4, 2024, at 11:20 am CT, in Chicago, Illinois.

Goldman Sachs 45th Annual Global Healthcare Conference
President and Chief Executive Officer Mark J. Foley is scheduled to present on Tuesday, June 11, 2024, at 8:00 am ET, in Miami, Florida.

Interested parties can access the live audio webcasts for the conferences from the Investor Relations section of the company's website at www.revance.com. The webcast replays will be available after the conclusion of the live presentations for approximately 90 days.

About Revance
Revance is a biotechnology company setting the new standard in healthcare with innovative aesthetic and therapeutic offerings that enhance patient outcomes and physician experiences. Revance’s portfolio includes DAXXIFY® (DaxibotulinumtoxinA-lanm) for injection and the RHA® Collection of dermal fillers in the U.S. Revance has also partnered with Viatris Inc. to develop a biosimilar to onabotulinumtoxinA for injection and Shanghai Fosun Pharmaceutical to commercialize DAXXIFY in China.

Revance’s global headquarters and experience center is located in Nashville, Tennessee. Learn more at Revance.com, RevanceAesthetics.com, DAXXIFY.com, HCP.DAXXIFYCervicalDystonia.com, or connect with us on LinkedIn.

“Revance”, the Revance logo, and DAXXIFY are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid® and RHA® are trademarks of TEOXANE SA.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240528756057/en/

Investors

Laurence Watts, 619-916-7620

laurence@newstreetir.com

Media

Revance@evolvemkd.com

Source: Revance Therapeutics, Inc.

FAQ

When will Revance present at the William Blair Growth Stock Conference?

Revance's CFO Tobin Schilke will present on June 4, 2024, at 11:20 am CT.

When is Revance presenting at the Goldman Sachs Global Healthcare Conference?

Revance's CEO Mark J. Foley will present on June 11, 2024, at 8:00 am ET.

How can I access Revance's investor conference presentations?

You can access live audio webcasts and replays on Revance's Investor Relations webpage.

For how long will the webcast replays be available?

Webcast replays will be available for approximately 90 days after the live presentations.